Ryo Nishikawa

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 10

Top Topics

Newly Diagnosed

Acute Lymphoblastic Leukemia

Top Venues

Current oncology (Toronto, Ont.)

Neuro-oncology advances

Japanese journal of clinical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Daiken Satake, Manabu Natsumeda, Kaishi Satomi, Mari Tada, Taro Sato, Noritaka Okubo, Keita Kawabe, Haruhiko Takahashi, Yoshihiro Tsukamoto, Masayasu Okada, Masakazu Sano, Haruko Iwabuchi, Nao Shibata, Masaru Imamura, Chihaya Imai, Hirokazu Takami, Koichi Ichimura, Ryo Nishikawa, Hajime Umezu, Akiyoshi Kakita, Makoto Oishi
Successful Multimodal Treatment of Intracranial Growing Teratoma Syndrome with Malignant Features. Current oncology (Toronto, Ont.) 31 (4) (2024)
Daiken Satake, Manabu Natsumeda, Kaishi Satomi, Mari Tada, Taro Sato, Noritaka Okubo, Keita Kawabe, Haruhiko Takahashi, Yoshihiro Tsukamoto, Masayasu Okada, Masakazu Sano, Haruko Iwabuchi, Nao Shibata, Masaru Imamura, Chihaya Imai, Hirokazu Takami, Koichi Ichimura, Ryo Nishikawa, Hajime Umezu, Akiyoshi Kakita, Makoto Oishi
Successful Multimodal Treatment of Intracranial Growing Teratoma Syndrome with Malignant Features. Current oncology (Toronto, Ont.) 31 (4) (2024)
Hajime Yonezawa, Yoshitaka Narita, Motoo Nagane, Kazuhiko Mishima, Yasuhito Terui, Yoshiki Arakawa, Katsunori Asai, Noriko Fukuhara, Kazuhiko Sugiyama, Naoki Shinojima, Arata Aoi, Ryo Nishikawa
Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma. Neuro-oncology advances 6 (1) (2024)
Daiken Satake, Manabu Natsumeda, Kaishi Satomi, Mari Tada, Taro Sato, Noritaka Okubo, Keita Kawabe, Haruhiko Takahashi, Yoshihiro Tsukamoto, Masayasu Okada, Masakazu Sano, Haruko Iwabuchi, Nao Shibata, Masaru Imamura, Chihaya Imai, Hirokazu Takami, Koichi Ichimura, Ryo Nishikawa, Hajime Umezu, Akiyoshi Kakita, Makoto Oishi
Successful Multimodal Treatment of Intracranial Growing Teratoma Syndrome with Malignant Features. Current oncology (Toronto, Ont.) 31 (4) (2024)
Daiken Satake, Manabu Natsumeda, Kaishi Satomi, Mari Tada, Taro Sato, Noritaka Okubo, Keita Kawabe, Haruhiko Takahashi, Yoshihiro Tsukamoto, Masayasu Okada, Masakazu Sano, Haruko Iwabuchi, Nao Shibata, Masaru Imamura, Chihaya Imai, Hirokazu Takami, Koichi Ichimura, Ryo Nishikawa, Hajime Umezu, Akiyoshi Kakita, Makoto Oishi
Successful Multimodal Treatment of Intracranial Growing Teratoma Syndrome with Malignant Features. Current oncology (Toronto, Ont.) 31 (4) (2024)
Hajime Yonezawa, Yoshitaka Narita, Motoo Nagane, Kazuhiko Mishima, Yasuhito Terui, Yoshiki Arakawa, Katsunori Asai, Noriko Fukuhara, Kazuhiko Sugiyama, Naoki Shinojima, Arata Aoi, Ryo Nishikawa
Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma. Neuro-oncology advances 6 (1) (2024)
Ryo Nishikawa, Fumiyuki Yamasaki, Yoshiki Arakawa, Yoshihiro Muragaki, Yoshitaka Narita, Shota Tanaka, Shigeru Yamaguchi, Akitake Mukasa, Masayuki Kanamori
Safety and efficacy of tumour-treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the Novo-TTF System: a prospective post-approval study. Japanese journal of clinical oncology (2023)
Ryo Nishikawa, Fumiyuki Yamasaki, Yoshiki Arakawa, Yoshihiro Muragaki, Yoshitaka Narita, Shota Tanaka, Shigeru Yamaguchi, Akitake Mukasa, Masayuki Kanamori
Safety and efficacy of tumour-treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the Novo-TTF System: a prospective post-approval study. Japanese journal of clinical oncology (2023)
Yoshiki Arakawa, Yoshitaka Narita, Motoo Nagane, Kazuhiko Mishima, Yasuhito Terui, Hajime Yonezawa, Katsunori Asai, Noriko Fukuhara, Kazuhiko Sugiyama, Naoki Shinojima, Arata Aoi, Ryo Nishikawa
Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I/II study of tirabrutinib. Neuro-oncology advances 5 (1) (2023)
Motoo Nagane, Koichi Ichimura, Ritsuko Onuki, Daichi Narushima, Mai Honda-Kitahara, Kaishi Satomi, Arata Tomiyama, Yasuhito Arai, Tatsuhiro Shibata, Yoshitaka Narita, Takeo Uzuka, Hideo Nakamura, Mitsutoshi Nakada, Yoshiki Arakawa, Takanori Ohnishi, Akitake Mukasa, Shota Tanaka, Toshihiko Wakabayashi, Tomokazu Aoki, Shigeki Aoki, Soichiro Shibui, Masao Matsutani, Keisuke Ishizawa, Hideaki Yokoo, Hiroyoshi Suzuki, Satoshi Morita, Mamoru Kato, Ryo Nishikawa
Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study. Cancers 14 (22) (2022)